Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis

Journal of Pediatrics

Volumn 162, Issue 1, 2013, Pages 205-207

  Morren, Marie Anne ^a   Hoppé, Anne ^b   Renard, Marleen ^a   Debiec Rychter, Maria ^a   Uyttebroeck, Anne ^a   Dubreuil, Patrice ^c   Martin, Ludovic ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

DCM; Diffuse cutaneous mastocytosis

Indexed keywords

CROMOGLYCATE DISODIUM; GENOMIC DNA; IMATINIB; KETOTIFEN; OXACILLIN; RANITIDINE; STEM CELL FACTOR RECEPTOR; STEROID; TRYPTASE;

ARTICLE; BONE MARROW; CASE REPORT; DIFFUSE CUTANEOUS MASTOCYTOSIS; DNA EXTRACTION; DRUG TOLERABILITY; ERYTHEMA; EXON; FEMALE; FEVER; GENE MUTATION; HOSPITALIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MASTOCYTOSIS; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN CULTURE; SKIN INFECTION; SOMATIC MUTATION; STAPHYLOCOCCUS AUREUS; UPPER RESPIRATORY TRACT INFECTION;

FEMALE; HUMANS; INFANT; MASTOCYTOSIS, CUTANEOUS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84871398707     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2012.08.035     Document Type: Article

References (10)

1. B. Wasag, M. Debiec-Rychter, P. Pauwels, M. Stul, H. Vranckx, and A.V. Oosterom Differential expression of KIT/PDGFRA mutant isoforms in epitheloid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site Mod Pathol 17 2004 889 894 (Pubitemid 38993772)
2. R. Heide, E. Zuidema, A. Beishuizen, J.C. Den Hollander, D. Van Gysel, and M.M. Seyger Clinical aspects of diffuse cutaneous mastocytosis in children: two variants Dermatology 219 2009 309 315
3. H. Koga, T. Kokubo, M. Akaishi, K. Iida, and S. Korematsu Neonatal-onset diffuse cutaneous mastocytosis: a case report and review of the literature Pediatr Dermatol 27 2010 1 5
4. 816V and other activating c-KIT mutations J Invest Dermatol 130 2010 804 815
5. M. Rastogi, L. Stork, B. Druker, C. Blasdel, T. Nguyen, and B.A. Boston Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia Pediatr Blood Cancer 59 2012 840 845
6. Y. Ma, S. Zeng, D. Metcalfe, C. Akin, S. Dimetrijevic, and J.H. Butterfield The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations Blood 99 2002 1741 1744 (Pubitemid 34533049)
7. C. Ustun, D. DeRemer, and C. Akin Tyrosine kinase inhibitors in the treatment of systemic mastocytosis Leuk Res 35 2011 1143 1152
8. K.M. Hoffmann, A. Moser, P. Lohse, A. Winkler, B. Binder, and P. Sovinz Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation Blood 112 2008 1655 1657
9. R.D. Barr Review: imatinib mesylate in children and adolescents with cancer Pediatr Blood Cancer 55 2010 18 25
10. A.M. Zamah, M.J. Mauro, B.J. Druker, K. Oktay, M.J. Egorin, and M.I. Cedars Will imatinib compromise reproductive capacity? Oncologist 16 2011 1422 1427